Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues:
Product sales	$ 0	$ 0	$ 0	$ 0
Costs and expenses:
Research and development	2,979,228	1,729,470	5,593,885	3,426,703
General and administrative	6,982,227	4,042,347	12,691,914	5,345,469
Acquired in-process research and development	5,848,886	0	5,848,886	686,998
Costs and expenses	15,810,341	5,771,817	24,134,685	9,459,170
Interest income, net	(320,462)	(13,072)	(369,046)	(19,801)
Foreign exchange gains	(479,540)	0	(550,649)	0
Changes in fair value of investment in equity securities	240,931	101,038	195,542	11,325
Net loss	(15,251,270)	(5,859,783)	(23,410,532)	(9,450,694)
Less: Income attributable to redeemable noncontrolling interest	61,901	0	76,260	0
Net loss attributable to CASI Pharmaceuticals, Inc.	$ (15,313,171)	$ (5,859,783)	$ (23,486,792)	$ (9,450,694)
Net loss per share (basic and diluted)	$ (0.16)	$ (0.07)	$ (0.25)	$ (0.12)
Weight average number of shares outstanding (basic and diluted)	95,717,052	86,029,692	95,683,598	78,663,271
Comprehensive loss:
Net loss	$ (15,251,270)	$ (5,859,783)	$ (23,410,532)	$ (9,450,694)
Foreign currency translation adjustment	(1,112,489)	(1,066,893)	(800,704)	(539,642)
Total comprehensive loss	(16,363,759)	(6,926,676)	(24,211,236)	(9,990,336)
Less: Comprehensive income attributable to redeemable noncontrolling interest	61,901	0	76,260	0
Comprehensive loss attributable to common stockholders	$ (16,425,660)	$ (6,926,676)	$ (24,287,496)	$ (9,990,336)